BMS-986207 + Immunotherapy for Solid Cancers

Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Waitlist Available

Sponsor: Bristol-Myers Squibb

No Placebo Group

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?This trial is testing a new drug called BMS-986207 alone and with other drugs, Nivolumab and Ipilimumab, in patients with severe solid cancers. These patients have cancers that are advanced or have spread. The drugs aim to help the immune system recognize and destroy cancer cells.

Eligibility Criteria

This trial is for adults with advanced solid tumors showing at least 1% PD-L1 expression. They should be relatively healthy, able to perform daily activities (ECOG status of 0 or 1), and have measurable disease by scans. People with primary brain tumors, only brain metastases, other active cancers needing treatment, serious heart conditions, or autoimmune diseases can't join.

Inclusion Criteria

My cancer has PD-L1 levels of 1% or higher, confirmed by a test within the last 3 months.

I am fully active or restricted in physically strenuous activity but can do light work.

My cancer can be measured on scans and was checked within the last 28 days.

Exclusion Criteria

My NSCLC has not been treated in its advanced or metastatic stage.

I have serious heart problems that are not under control.

I have an autoimmune disease.

I have another cancer that needs treatment at the same time.

Treatment Details

The study tests BMS-986207 alone and in combination with Nivolumab or both Nivolumab and Ipilimumab. It aims to find out how safe these treatments are and how well they work against advanced solid tumors that have spread.

6Treatment groups

Experimental Treatment

Group I: Part 2C: Triplet ExpansionExperimental Treatment3 Interventions

Group II: Part 2B: Expansion Combination TherapyExperimental Treatment2 Interventions

Group III: Part 2A: Expansion MonotherapyExperimental Treatment1 Intervention

Group IV: Part 1C: Triplet CohortExperimental Treatment3 Interventions

Group V: Part 1B: Dose Escalation Combination TherapyExperimental Treatment2 Interventions

Group VI: Part 1A: Dose Escalation MonotherapyExperimental Treatment1 Intervention